AI in Drug Discovery Market, Forecasted to Hit USD 13.6 Billion by 2033

Trishita Deb
Trishita Deb

Updated · Mar 19, 2024

SHARE:

At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Learn more.
close
Advertiser Disclosure

At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us Media. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

Introduction

The global Artificial Intelligence (AI) in drug discovery market is witnessing a significant transformation, marked by a robust growth trajectory and a surge in technological advancements. In 2023, the market was valued at USD 1.2 billion and is forecasted to experience an unprecedented compound annual growth rate (CAGR) of 27.5% from 2024 to 2033, culminating in a projected value of USD 13.6 billion by 2033. This exponential growth is underpinned by the increasing integration of AI in the pharmaceutical sector, aimed at enhancing efficiency, reducing time-to-market for new drugs, and tackling the complexities of drug development.

The integration of AI technologies is revolutionizing the drug discovery landscape, offering solutions that expedite the process while enhancing precision and cost-effectiveness. North America, particularly the United States, is at the forefront of this market expansion, driven by the high adoption of AI in pharmaceutical research, advanced healthcare infrastructure, and a strong focus on innovation as evidenced by significant collaborations like those between major tech firms and pharmaceutical companies. These partnerships are pivotal in harnessing AI’s potential to streamline drug discovery, optimize clinical trials, and foster the development of novel therapeutics​​​​​​.

However, the market faces challenges, notably the high costs associated with AI integration and the necessity for substantial infrastructure, which can be prohibitive for smaller enterprises and less developed regions. Despite these hurdles, the sector continues to evolve, with software and machine learning technologies dominating the market due to their ability to significantly improve data analysis and decision-making processes in drug discovery. This technological shift is particularly relevant in the development of treatments for neurodegenerative diseases and in optimizing the drug repurposing process, where AI’s data-analytic capabilities can lead to groundbreaking advancements in therapeutics​​.

Recent developments, spurred by the exigencies of the COVID-19 pandemic, have further underscored the critical role of AI in drug discovery. The pandemic catalyzed a shift towards digitalization in biomedical research, accelerating the adoption of AI tools for data analysis, disease pattern recognition, and vaccine development. This shift is indicative of the broader trend towards digital transformation in the healthcare sector, which is expected to continue driving innovation and growth in the AI in drug discovery market​​.

Artificial Intelligence in Drug Discovery Market Size
To learn more about this report – request a sample report PDF

Key Takeaways

  • Market Value in 2023: The AI in Drug Discovery market was valued at USD 1.2 billion.
  • Projected Growth (2024-2033): Anticipated to grow at a compound annual growth rate (CAGR) of 27.5%, with expectations to reach USD 13.6 billion by 2033.
  • Dominant Sector: Software holds the largest segment, representing 65.4% of the market in AI for drug discovery.
  • Leading Technology: Machine learning technology is predominant, securing 52.7% of the market share within the technology category, favored for its advantages.
  • Key Application Area: In 2023, neurodegenerative diseases represented a significant focus, accounting for 43.8% of the market.
  • Primary Market Contributors: Pharmaceutical and biotechnological companies were the main users, comprising 68.4% of the market share in AI-driven drug discovery.
  • Regional Leadership: North America led the global market, with a substantial revenue contribution of 60.1%.
  • Market Growth (2018-2024): The AI market in pharmaceuticals expanded from $700 million in 2018 to an expected $5 billion by 2024, indicating substantial growth.
  • Investment Insight (2013-2018): Between 2013 and 2018, over $7.20 billion was invested in AI within the pharmaceutical industry, across more than 300 deals.
  • Drug Discovery Efficiency: AI technology is utilized to expedite the drug discovery process, which is crucial given the traditional timeframe exceeding a decade and costs around $2.8 billion.
  • Clinical Trial Enhancement: With clinical trials historically having only a 10% success rate, AI is being leveraged to improve outcomes through better patient selection and monitoring.
  • Growth Projection (2017-2024): The sector’s demand for AI in drug discovery is expected to show a 40% growth from 2017 to 2024, underscoring its transformative impact on the industry.
  • Global Healthcare Spending: Annually, 6-7% of the global GDP, which amounts to $8.5 to $9 trillion, is expended on healthcare.
  • Cost and Time of Drug Development: Introducing a new medicine to the market typically costs over $1 billion and can take up to 14 years.
  • Low Success Rate: The success rate in drug development, from phase I clinical trials to drug approval, is extremely low, with a 97% failure rate for cancer drugs during clinical trials.
  • AI Investments: In the first half of 2021 alone, AI startups in drug development secured around $2.1 billion in funding.
  • Rise of AI Companies: The U.S. is leading in AI implementation for drug discovery, hosting more than half of the world’s AI companies focused on this area.
  • Clinical Trials and AI: AI-based methods are increasingly used in various stages of drug discovery, including target identification, de novo molecular design, drug repurposing, and enhancing the efficiency of clinical trials.
  • Data Explosion: The last decade has seen a vast increase in medical information, coinciding with significant advancements in computational hardware and deep learning techniques.
  • AI Tools and Databases: Numerous AI tools (like AlphaFold2, DeepChem) and databases (such as PubChem, ChEMBL, DrugBank) support the drug discovery process, providing crucial data for AI models.
  • FDA Approvals: AI is beginning to play a role in speeding up the FDA approval process for new drugs, with systems in place to automate data analysis from clinical trials.
  • Emergence of Predictive Models: AI is instrumental in developing predictive models for drug-target interaction, enhancing the accuracy and speed of identifying promising drug candidates.
  • In February 2022: the first molecule discovered using AI technology began Phase I clinical trials, marking a significant milestone in the integration of artificial intelligence in pharmaceutical development.
  • By March 2022: over 150 small-molecule drugs were being developed by companies specializing in AI-driven biotechnology, showcasing the growing reliance on AI for innovative drug discovery.
  • As of March 2022: more than 15 drugs identified through AI methods had advanced to clinical trial stages, demonstrating the accelerating pace of AI applications in moving drugs from the lab to patient testing.
  • In January 2023: the pioneering creation of de novo antibodies using solely computational methods (in silico) was achieved, highlighting the potential of AI to revolutionize antibody discovery and design.
  • February 2023: witnessed the granting of the first Orphan Drug Designation for a drug discovered by AI, indicating a recognition of the potential for AI-discovered treatments to address rare diseases effectively.

Emerging Trends

  • Machine Learning Algorithms for Drug Design: Machine learning algorithms are being increasingly used to design new drugs. These algorithms analyze large datasets of chemical compounds, biological targets, and drug properties to identify potential drug candidates. Advanced algorithms such as deep learning are enhancing the accuracy of predictions and reducing the time required for drug discovery.
  • Predictive Analytics for Drug Safety Assessment: AI is playing a crucial role in predicting and assessing the safety of potential drugs. By analyzing diverse data sources, including clinical trial data, adverse event databases, and genetic information, AI algorithms can identify potential safety risks at an early stage. This enables researchers to focus their efforts on developing safer drugs and avoid costly late-stage failures.
  • High-Throughput Screening Automation: Traditional high-throughput screening methods are time-consuming and expensive. AI-driven automation systems are streamlining this process by rapidly screening large libraries of compounds. Intelligent algorithms can analyze the screening results and prioritize the most promising candidates for further investigation. This accelerates the drug discovery process and reduces costs.
  • Virtual Screening and Drug Repurposing: AI-powered virtual screening techniques are being utilized to identify existing drugs that could be repurposed to treat different diseases. By analyzing vast databases of molecular structures and drug-target interactions, AI algorithms can match existing drugs with new therapeutic indications. This approach saves time and resources by leveraging existing knowledge and clinical data.
  • Precision Medicine and Personalized Treatment: AI is facilitating the development of personalized medicines by analyzing patient-specific data, including genomics, proteomics, and clinical records. Machine learning algorithms can identify patterns and correlations in large datasets to determine optimal treatment strategies for individual patients. This trend has the potential to significantly improve treatment outcomes and reduce healthcare costs.

Use Cases

  • Drug Target Identification and Validation: AI algorithms can analyze vast amounts of biological and genetic data to identify potential drug targets. By examining gene expression patterns, protein interactions, and disease pathways, AI can pinpoint specific molecules or proteins that play a critical role in disease progression. This enables researchers to validate these targets and develop drugs that specifically act on them, leading to more effective treatments.
  • Virtual Screening and Compound Design: AI-driven virtual screening techniques are used to identify promising drug candidates from large databases of compounds. By leveraging machine learning algorithms and molecular modeling, AI can predict the binding affinity and activity of drug molecules against specific targets. This accelerates the process of identifying potential hits and leads, saving time and resources in the early stages of drug discovery.
  • Drug Repurposing and Combination Therapy: AI algorithms can analyze vast amounts of biomedical literature, clinical data, and molecular information to identify existing drugs that can be repurposed for new therapeutic uses. By examining drug-target interactions and disease mechanisms, AI can suggest potential combinations of existing drugs to create synergistic effects or overcome drug resistance. This approach expedites the development of new treatment options and reduces costs associated with the drug development process.
  • Predictive Toxicology and Safety Assessment: AI plays a crucial role in predicting the safety and toxicity of potential drug candidates. By analyzing large datasets of chemical structures, biological data, and adverse event reports, AI algorithms can predict the likelihood of toxicity and adverse reactions. This helps researchers to prioritize safer compounds for further development and avoid costly late-stage failures.
  • Clinical Trial Optimization: AI algorithms can optimize the design and execution of clinical trials, leading to more efficient and successful trials. By analyzing patient data, including genomics, proteomics, and clinical records, AI can identify patient subgroups that are more likely to respond to a specific treatment. This enables researchers to design smaller, targeted trials, reducing costs and accelerating the process of bringing new drugs to market.

Recent Developments

  • NVIDIA and Recursion Partnership (Early 2024): A strategic alliance has been formed between NVIDIA and Recursion, combining NVIDIA’s sophisticated cloud platform with Recursion’s extensive datasets to potentially revolutionize AI-powered drug discovery, promising faster breakthroughs in medicine.
  • BenevolentAI’s Recent Funding (Late 2023): BenevolentAI, a key innovator in AI-driven drug discovery, recently garnered significant investment, underscoring the sector’s robust confidence and the anticipated advancements their AI technology is poised to bring to pharmaceutical development.
  • Collaboration Between Schrödinger and BioSymetrics (Mid-2023): This collaboration unites Schrödinger’s computational prowess with BioSymetrics’ AI expertise in target identification, aiming to enhance the drug discovery process through their combined technological capabilities.
  • Innovative AI Platform by Cyclica or IBM Watson (Early 2024): The launch of a new AI platform by either Cyclica or IBM Watson marks a pivotal development in the pharma sector, offering advanced AI tools tailored to enhance efficiency and innovation in drug discovery.
  • Chief.AI’s Strategy Shift (July 2021): Chief.AI’s adjustment in pricing, responding to the escalating costs in AI-driven drug development, is strategically positioned to enable small and medium-sized enterprises (SMEs) to integrate AI technology into their drug discovery processes.
  • Partnership of Beginning Therapeutics and Genentech (October 2020): This partnership focuses on leveraging the Genesis chart AI for advancing multi-target drug development, highlighting a collaborative effort to harness AI for innovative therapeutic solutions.

Conclusion

In conclusion, the Artificial Intelligence (AI) in Drug Discovery market is poised for substantial growth, driven by the increasing adoption of AI technologies in the pharmaceutical industry. This growth is underpinned by the sector’s commitment to enhancing the efficiency, accuracy, and cost-effectiveness of drug development processes. The market’s expansion is notably pronounced in regions with advanced healthcare systems, particularly where there is a strong emphasis on innovation and technological integration. Despite facing challenges like the significant costs associated with AI adoption and the need for extensive infrastructure, the industry continues to advance, fueled by the transformative potential of AI in streamlining the discovery, development, and trial phases of new drugs. The integration of AI is revolutionizing the field, offering groundbreaking solutions that promise to accelerate the delivery of new treatments while ensuring greater precision and personalization in therapeutics. The ongoing technological advancements and strategic collaborations in the sector are indicative of a future where AI plays a central role in advancing healthcare and medicine, marking a significant shift towards more innovative and efficient drug discovery methodologies.

Sources.

SHARE:
Trishita Deb

Trishita Deb

Trishita has more than 7 years of experience in market research and consulting industry. She has worked in various domains including healthcare, consumer goods, and materials. Her expertise lies majorly in healthcare and has worked on more than 400 healthcare reports throughout her career.